Form 4: Mirum Pharma CMO Granted 49,900 Equity Awards

Mirum Pharmaceuticals' Chief Medical Officer, Joanne Quan, was granted stock options, restricted stock units, and performance restricted stock units totaling 49,900 shares on January 28, 2026.

Summary

• Joanne Quan, Chief Medical Officer of Mirum Pharmaceuticals, Inc. (MIRM), was granted a total of 49,900 derivative securities on January 28, 2026.
• This includes 18,140 stock options with an exercise price of $100.85, which will vest over approximately four years.
• Additionally, 11,760 Restricted Stock Units (RSUs) were granted, vesting in three equal annual installments starting January 28, 2027.
• 20,000 Performance Restricted Stock Units (PSUs) were also granted, with performance criteria determined to have been met on January 28, 2026, and vesting in two tranches on March 15, 2026 (2/3 of shares) and March 15, 2027 (1/3 of shares).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as significant equity grants to a key executive like the Chief Medical Officer demonstrate confidence in her continued contribution and align her incentives with the company's long-term success.

Positives

• The Chief Medical Officer received a significant equity grant totaling 49,900 shares, aligning her interests with long-term shareholder value.
• The vesting of performance-based restricted stock units indicates that certain company performance criteria have been met.

Industry Context

StockSavvy.ai notes that executive equity grants are a standard practice in the biotechnology and pharmaceutical industry, serving to incentivize leadership and align their long-term interests with shareholder value. Such grants are common for Chief Medical Officers, reflecting their critical role in drug development and regulatory success.

Stakeholder Impact

• Shareholders: Potential for increased alignment of executive interests with shareholder value through equity ownership.
• Employees: May signal management stability and confidence in the company's future.

Next Steps

• Vesting of 1/4th of stock options one year after January 28, 2026, with the remainder vesting monthly over 36 months.
• Vesting of 1/3rd of Restricted Stock Units on each anniversary of January 28, 2026, until fully vested on the three-year anniversary.
• Vesting of 2/3 of Performance Restricted Stock Units on March 15, 2026.
• Vesting of 1/3 of Performance Restricted Stock Units on March 15, 2027.

Key Dates

Keywords

Mirum Pharmaceuticals, MIRM, Joanne Quan, Chief Medical Officer, Insider Transaction, Form 4, Stock Options, Restricted Stock Units, Performance Stock Units, Equity Grant, Executive Compensation